features: Clinical Practice

The Phase III EV-302/KEYNOTE-A39 (NCT04223856) trial demonstrated that the combination of enfortumab vedotin and pembrolizumab significantly improved overall survival (OS)…

Endometrial cancer is the most common gynecological cancer, where approximately 417,000 cases and 100,000 deaths were reported worldwide in 2020.1…

Initial data from the Phase III Breast Cancer Weight Loss Study (BWEL) (NCT02750826) has shown promising results for a telephone-based…

Primary results from the Phase III SPOTLIGHT (NCT03504397) trial demonstrated a significant survival benefit for patients with Claudin18.2 (CLDN18.2)-positive, HER2-negative,…

VJOncology is excited to present the latest data and developments in the bladder cancer field, with comments from Yohann Loriot, Jonathan…

On December 9th 2022, The US Food and Drug Administration (FDA) permitted the approval of atezolizumab for adult and pediatric…

The U.S. Food and Drug Administration (FDA) have approved tremelimumab in combination with durvalumab and platinum-based chemotherapy for metastatic non-small…

VJOncology are excited to highlight the latest in immuno-oncology from the 37th Annual Meeting of the Society for Immunotherapy in…

As of the 23rd March 2022, the U.S. Food and Drug Administration (FDA) has approved 177Lu-PSMA-617 (a.k.a. Lu 177 Vipivotide…

VJOncology are excited to present some key abstracts and trial updates announced at this year’s virtual St. Gallen Breast Cancer…

The Enhanced Recovery After Surgery (ERAS) approach was initially pioneered for colorectal surgery by a group of surgeons in northern…